text:
Results 1 to 3 of 3
Thread: Query dialog box entry
02-19-08, 11:22 #1Registered User
- Join Date
- Aug 2005
- Location
- Delaware
- Posts
- 139
Unanswered: Query dialog box entry
I have a query with one field that accepts user input ( [Enter selection here[ ) as "criteria". When I run the query and enter the info when prompted (i.e. "1" (no quotes)) everything runs fine. If I eliminate the user criteria selection prompt in the selected field, and run the query directly, I can enter selection such as " "1" or "2" " and the query will return all 1's and 2's. My question is... is it possible to have the user select multiple criteria, just as I can when I run the query without the user prompt, from within the dialog prompt box? I tried entering the user prompt just as I do when running the query directly, but nothing was returned, i.e I entered " "1" or "2" " in the dialog box.
02-19-08, 14:19 #2Registered User
- Join Date
- Apr 2004
- Location
- metro Detroit
- Posts
- 634
I think you need to use a form and build a filter or where clause.
02-19-08, 20:04 #3L33t Helpa Munky
- Join Date
- Nov 2007
- Location
- Adelaide, South Australia
- Posts
- 4,049
Yup. Making your own dialog box would seem to be the logical way to goOwner and Manager of
CypherBYTE, Microsoft Access Development Specialists.
Microsoft Access MCP.
And all around nice guy!
"Heck it's something understood by accountants ... so it can't be 'that' difficult..." -- Healdem
"...teach a man to code and he'll be frustrated for life! " -- georgev


text:
Forgot your password? Enter the email address you signed up with and we will send you a link to create a new password.
Your password reset has been submitted to the address provided.
Colors could not be determined.
Standard character mark
Retail store services featuring convenience store items and gasoline
Business in Brentwood, TN

subset: commoncrawl


text:
The Books Everyone Should Love
(and We Hope You Will)
Copyright © 2016 Sue Clancy
Sue Clancy is a professional fine artist and illustrator with affection for the visual story. She is represented by 3 different commercial art galleries. Her illustrations have most recently appeared in Oregon Coast Magazine, Raven Chronicles and The Tishman Review. When not cutting and gluing handmade paper to make her artwork she can be found reading a library book alongside a dachshund named Rusty. More of Sue's work can be seen at www.sueclancy.com
Life In, Life Out by Avital Gad-Cykman
Matter Press announces the release of its ninth title, Avital Gad-Cykman's Life in, Life Out. This spirited collection of flash fiction deals with war and resistance, parenthood and childhood, passion and longing. There's the slant of exile in it, as it reflects the author's situation: an Israeli, living in Brazil and writing in English. These thirty-four stories have been published in places like W.W. Norton's Flash International Anthology, Los Angeles Review, Salon, and Prism International. Avital's work has also appeared in Glimmer Train, McSweeney's Quarterly, and Michigan Quarterly Review.
My Life at First Try by Mark Budman
This semi-autobiographical debut novel chronicles the life of Alex, born in Siberia in 1950, and his dreams of becoming a writer and of meeting Annie, his distant American cousin. As a child, Alex observes a group of foreign tourists do something that non-drunk Soviet adults seldom do: they laugh. Alex yearns to become one of them—a free and happy foreigner. Those aspirations quickly fade as Alex begins to encounter the absurdities and constraints of living in a society where conformity is institutionalized. Hilarious and sometimes sobering, the book's short chapters chronicle making it through the army, mastering the English language, sex, and meeting the girl of his dreams. In 1980, Alex and his young family finally get the chance to move to America. There he realizes that he is finally a foreigner—not the happy foreigner of his dream, but an alien. Ultimately, Alex finds his own place in the world, despite the fact that having the right "to vote for an elephant or an ass" does not necessarily guarantee self-fulfillment.
Calling New Delhi for Free by Susan O'Neill
Technology first rocked our world when a lightning bolt zapped a bush at the entrance to a cave, and First Man crawled out and stuck his hand into the mystical blaze. Centuries later, we still find technology fascinating, mysterious, distracting, vital and Wow! Shiny!–and it still fries our grasping, hapless human hands, not to mention our grasping, hapless human brains. These short essays are all about that tender point where the finger meets the flame, where the ecstasy and the pain live–and where the sweet, dark humor so often lurks. Most of them simply examine the craziness of everyday life. Some spring from weird travel experiences. Some pick at politics, niggle at religion, worry at war. They're set in Starbucks, in my kitchen, in Viet Nam, in India, on a Russian train and a Greyhound bus; in Massachusetts, Indiana, Brooklyn and Times Square; in WalMart and Golden Corral, and at the second inauguration of Barack Obama. All have been published somewhere before. In all the pieces, there is a tie to technology, be it as strong as an anchor cable, or as tenuous as a spiderweb. This gives me a lot of leeway–because what, in this modern world, *isn't* tied to technology? A final disclaimer: you certainly don't have to be tech savvy to enjoy this book. You just have to be a human being with bandaids on your fingers. Which pretty much describes us all.
86 of the best very short stories from around the world, almost all contemporary though with a few classics, too. Chris Merrill, director of U of Iowa International Writing Program joins Shapard and Thomas as coeditor. Sherman Alexie, Linh Dinh, Randa Jarrar, Franz Kafka, Stuart Dybek, Alberto Chimal, Qui Xiaolong, Natalie Diaz, Naguib Mahfouz, Bess Winter.
I'd Walk with My Friends If I Could Find Them by Jesse Goolsby
Jesse Goolsby, whose flash "Highfives and Pitchforks" was published in Vestal Review in 2010, has his debut novel, "I'd Walk with My Friends If I Could Find Them," coming out June 2nd from Houghton Mifflin Harcourt.
Simple Pleasures by A.W. Marshall
Simple Pleasures marks the debut of A.W. Marshall's curiously addicting fiction. In Marshall's stories hearts can literally be touched, actually–grasped, and a rolling Head can terrorize a town. Here the power of sex both attracts and repels: lovers fall off a dizzy perch among branches, a plunge that alters the lives of others for decades; the accidental glancing touch of two strangers binds them to an increasingly disorderly life of physical pleasure; and the confluence of a cache of pornographic drawings and mistaken identity allow a man to escape his dreary life. Surprises appear at nearly every turn in these intriguing, original stories, and Marshall orchestrates them beautifully.
—Philip Graham, author of How to Read an Unwritten Language and The Art of the Knock
Condensed to Flash: World Classics edited by Mark Budman and Susan O'Neill
"Condensed to Flash: World Classics" is a work that brings new life to the old classics. It's an anthology for people who love concise writing that is intense, entertaining and educational. It's an anthology that brings you the familiar in a new way.
Most classics are far from dry and boring stuff that was left to lie half-forgotten on the dusty back shelves of a school or college library. Still, it's not a secret that they may lose some of their appeal to busy generations raised with computers and social media. This anthology to the rescue. Although condensed, our stories maintain the essence and allure of the classics while being short, fun, contemporary, engaging, yet deep and witty. Yes, flash literary fiction is even more cool and compelling than zombies, vampires and however many shades of grey are out there.
This anthology features variations on the themes of world classics, each condensed to 500 words or fewer. They are not summaries or CliffsNotes, but literary stories that stand on their own. As Jules Verne said, "You are going to visit the land of marvels."
RIFT by Kathy Fish and Robert Vaughan
A stunning collaboration from Robert Vaughan and Kathy Fish, two masters of flash fiction, who've blended their work together in a vibrant explosion that is all of these things: evocative, heart wrenching, rare in the wild. The stories in RIFT explore the gamut of human connection and conflict, where emotions run deep beneath the surface. Divided into four sections: Fault, Breach, Tremor, and Cataclysm, writers Fish and Vaughan thread together their tales of strange encounters, mishaps, accidents, and disrepair. The world of RIFT is riven, tumultuous, and haunting. In here, danger lurks and the fallible human heart lay exposed and vulnerable. Fish and Vaughan leave their readers spellbound, mystified, and eager for the next story.
THE OTHER MAN is an artistic collaboration by and about gay men and their relationships. If you've ever been the other man, had him invade your life, or if you're just plain curious about this beguiling, sexy and unpredictable creature, then this anthology of personal essays is for you. Twenty–one of our most acclaimed authors–many Lambda Award Winners and Finalists, such as Rob Byrnes, Jeff Mann, TomMendicino, Erik Orrantia, Felice Picano and David Pratt, write candidly about either being the other man, suffering the other man or having their relationships tested by infidelity.
Brevity by David Galef
In Brevity, David Galef provides a guide to writing flash fiction, from tips on technique to samples by canonical and contemporary authors to provocative prompts that inspire powerful stories in a little space. Galef traces the genre back to its varied origins, from the short-short down to nanofiction, with examples that include vignettes, prose poems, character sketches, fables, lists, twist stories, surrealism, and metafiction. The authors range from the famous, such as Colette and Borges, to today's voices, like Roxane Gay and Bruce Holland Rogers. A writer and longtime creative writing teacher, Galef also shows how flash fiction skills translate to other types of writing. Brevity is an indispensable resource for anyone working in this increasingly popular form. For more information, see www.davidgalef.com/brevity.
What She Was Saying by Marjorie Maddox Hafer
In these powerful stories, What She Was Saying softens the already thin line between hope and hopelessness, between perseverance and despair, between what can and cannot be said. A finalist for the Katherine Anne Porter and Eludia book awards—as well as a semifinalist for Black Lawrence Press's Hudson, Eastern Washington University's Spokane, and Leapfrog Press's book prizes—What She Was Saying gives voice to the lives we all need to hear.
FUNHOUSE by Robert Vaughan
FUNHOUSE by Robert Vaughan (Unknown Press) is brilliant, slippery pieces of flash fiction and longer form prose from the author of Addicts & Basements, and Rift(with Kathy Fish). Robert Vaughan is unrivaled in his ability to surprise, stimulate and explore. A magician with a typewriter. He returns here with stories to hypnotize in the Tunnel of Love, beguile in the Hall of Wonders, spin you around on the Tilt o' Whirl.
THE MISSING GIRL by Jacqueline Doyle
In these dark and edgy stories, Jacqueline Doyle has made a dispassionate study of the degradation of girls and the twisted hearts of those who harm them. Most chilling is the ease with which these characters fall prey to violence and how quickly depravity finds its way past the surface of ordinary situations. Prepare to be very disturbed.
—Elizabeth McKenzie, author of MACGREGOR TELLS THE WORLD and THE PORTABLE VEBLEN (2016 National Book Award Finalist)
A New Dawn, by Sudha Balagopal
At forty-eight, Usha has never dated. Like all good Indian girls, she married the man whom her family chose. Twenty-three years after success-driven Raja brought her to Phoenix, he leaves her a widow. Alone and aching, she does the unthinkable–registers on a dating website. Through pitfalls and blunders, Usha navigates new territory, discovering what she wants from life and love.


text:
A Bathroom made in Cinema 4D, which is saved as .3ds so you can open it with most 3d editing softwares.It's high poly and the models are made really good, spent quite some time.
* All the models are uploaded by users, thus free3d.com is not responsible for their content. For any copyright infringements / takedowns (if you are the copyright holder) please contact us.


text:
|Home > Kilian
♂ Kilian
What does Kilian mean?
Kilian as a name for boys. The meaning of Kilian is "bright-headed". Kilian is an alternate form of Killian (Irish, Gaelic): from the same root as Kelly.
VariationsCREATIVE FORMS
Kilian Landon (K.L.), ..
How popular is Kilian?
Kilian is an unusual first name for men but a very prominent last name for all people (#10460 out of 150436, Top 7%). (2000 U.S. DEMOGRAPHICS)
Kilian entered the list in 2014 and reached its top rank of #1330 in the U.S. in 2015. (TOP 2000 NAMES, 2015)
Which version is better?
The only other popular related form of Kilian (#1330 VIA LATEST LIST) is Killian (#348). These relations of Kilian were at the apex of their popularity in 2015 (USAGE OF 0.1%). Killian is the most contemporarily stylish boy name here.
Similar Names
Kilian is pronounced similarly to Cailean, Cailin, Calan, Callan▲, Colan, Colin, Cullan, Kaelan, Kaelin, Kalen, Kalin, Keallan, Keelan, Keelin, Keilan, Keillan, Kelan, Kellan▲, Kellen, Kellin, Kelwinn, Kelwyn, Kylan▲, Kylen▲ and Quillan. Other suggested similar-sounding names are Ailean, Ailin, Bivian, Cillian, Dilan▲, Dillan, Eilan, Eilean, Eilian, Eirian, Elian, Emilian, Filian, Fillan, Finian, Gilean, Gilian, Gillan, Gillian, Gilman, Julian▲, Kalani, Kalman, Kelvan, Kian▲, Kiean, Kienan, Kieran▲, Kiran, Kirwan, Klein, Kleon, Kline, Midian, Milan▲, Ninian, Silvan, Tilman and Vivian▼. These names tend to be more commonly used than Kilian.See names in meaning and etymology.


text:
With First Tutors: Music you can search for a Stroud bagpipes tutor. Bagpipes tuition are a brilliant way to begin an entertaining new hobby, pick up a new talent and attain confidence in bagpipes. Please use our service to search for Stroud bagpipes teachers and select which best matches your requirements so you can begin your bagpipes tuition in Stroud straight away!
First Tutors: Music is the only place to contact Stroud bagpipes tutors in the UK, helping you find Stroud bagpipes tuition close to you and Stroud tutors to help with any instrument like piano, violin or guitar. We can help you find Stroud bagpipes lessons or a one-to-one Stroud bagpipes tutor to prepare for bagpipes grades and improve your bagpipes skills! We order Stroud bagpipes teachers near you according to their tuition charges and proximity to you.
If you are a bagpipes tutor wishing to offer bagpipes lessons in Stroud or anywhere else across the UK, please register with First Tutors: Music or find out more about us here. Becoming a Stroud bagpipes tutor is a fantastic way to improve your own skills by providing bagpipes lessons while helping others, all in the Stroud area!


text: So I am terribly missing the iPod controls I had on my iphone with the earbuds. Are there any out there that will allow volume increase/decrease or song change, pause/play? It's a pain in the butt to have to pull this thing outta my pocket every time I wanna switch a track or something. Anyone?


text:
Can anyone help to get into dbl distributing?
From their requirements:
Operate a stand-alone website with an active shopping cart.
(NOT selling on eBay, Craig's List, Amazon, etc).
This site must be functional at the time of your application
This is kind of strange. I mean I could be re-selling shoes or Electronics or Sports anything and what should I do then? Create website for each category?
What is the point asking for a stand-alone website which could be selling Shoes,
while their site wholesale electronics?
I do have site but it's actually re-selling Amazon products.. Can any of you guys
supply your website with the Shopping Card so I can reference it when applying for
re-seller? I don't know how they going to validate who is the owner (probably send email to registered domain), i could be a partner, let's say, for example. Anyone can help? Thanks. I do have all the Business and Tax licenses..
Thank you.


text:
|Publication number
|Publication type
|Application number
|Publication date
|Dec 21, 2010
|Filing date
|Jul 21, 2005
|Priority date
|Nov 4, 1997
|Fee status
|Also published as
|Publication number
|Maria Palasis, James J. Barry, Louis Ellis, Gary L. Hendrickson, Kent D. Harrison, Lixiao Wang
|Original Assignee
|Boston Scientific Scimed, Inc.
|Export Citation
|BiBTeX, EndNote, RefMan
|Patent Citations (70), Non-Patent Citations (27), Referenced by (1), Classifications (32), Legal Events (2)
|External Links: USPTO, USPTO Assignment, Espacenet
This application is a continuation of and claims priority to, U.S. patent application Ser. No. 10,837,612, filed May 4, 2004, now U.S. Pat. No. 6,953,466 and entitled "METHODS FOR DELIVERING A THERAPEUTIC IMPLANT TO TISSUE," which is a continuation of Ser. No. 09/70931 U.S. Pat. No. 6,749,617, filed Nov. 8, 2000, entitled "CATHETER AND IMPLANTS FOR THE DELIVERY OF THERAPEUTIC AGENTS TO TISSUES," which is a continuation-in-part of, and claims priority to Ser. No. 09/516,531, U.S. Pat. No. 6,238,406, filed Mar. 1, 2000, entitled "PERCUTANEOUS MYOCARDIAL REVASCULARIZATION GROWTH FACTOR MEDIUMS AND METHODS" which is a divisional of Ser. No. 09/184,220 filed Nov. 2, 1998, now U.S. Pat. No. 6,045,565, which issued Apr. 4, 2000 and is entitled "PERCUTANEOUS MYOCARDIAL REVASCULARIZATION GROWTH FACTOR MEDIUMS AND METHODS" which claims the priority benefit of U.S. Provisional Patent Application Ser. No. 60/064,210, filed Nov. 4, 1997, entitled "TRANSMYOCARDIAL REVASCULARIZATION GROWTH FACTOR MEDIUMS AND METHOD" and U.S. Pat. No. 5,968,059, which issued Oct. 19, 1999, entitled "TRANS MYOCARDIAL REVASCULARIZATION CATHETER AND METHOD".
The present invention relates generally to the application of non-invasive techniques to the delivery of therapeutic agents. Specifically, the present invention relates to an injection catheter for the treatment of heart diseases or other organs by the injection of therapeutic agents and/or placement of implants.
A number of techniques are available for treating heart disease and diseases of other organs percutaneously. An example of one such technique is percutaneous myocardial revascularization (PMR). This procedure is performed to increase blood perfusion through the myocardium of a patient. For example, in some patients, the number of lesions in coronary vessels is so great, or the location so remote in the patient vasculature, that restoring blood flow to the heart muscle is difficult. Percutaneous myocardial revascularization (PMR) has been developed as an alternative to techniques which are directed at bypassing or removing lesions. PMR is performed by boring holes directly into the myocardium of the heart. Positive results have been demonstrated in some human patients receiving PMR treatments. These results are believed to be caused in part by blood flowing from within a heart chamber through patent holes formed by PMR to the myocardial tissue. Suitable PMR holes have been proposed to be burned by laser, cut by mechanical means, and burned by radio frequency devices. Increased blood flow to the myocardium is also believed to be caused in part by the healing response to wound formation, specifically, the formation of new blood vessels in response to the newly created wound.
What remains to be provided are improvements and devices for enhancing the effectiveness of percutaneous myocardial revascularization. What also remains is the extension of these and other refinements to the treatment of various types of heart disease and diseases of other organs.
The present invention includes devices and methods for treatment of heart disease and diseases of other organs. The primary focus of the devices and methods of the present invention is the treatment of heart disease, but it should be appreciated that, as explained in more detail below, the devices and methods can be used to treat the diseases of other organs. In some instances, the techniques will vary depending upon the disease being treated.
An exemplary embodiment of the present invention includes, devices and methods for increasing blood circulation to the myocardium. Circulation can be increased through patent holes into the myocardium from a heart chamber and from new blood vessel growth. New blood vessels can provide blood supplied from within a heart chamber, such as the left ventricle, and from pre-existing vessels in nearby healthy heart tissue. New vessel growth can be promoted by the healing response to wounds created in accordance with the present invention. New vessel growth can also be promoted by angiogenic substances supplied to the myocardium in accordance with the present invention.
One set of methods according to the present invention utilizes implants such as tubes implanted into the myocardium, preferably from within the heart, delivered by a catheter. The tubes preferably contain, or are coated with, an angiogenic substance capable of being released over time. These tubes can be biodegradable, being absorbed by the body, some embodiment tubes leaving a patent hole in the myocardium surrounded by the absorbed angiogenic material. Other PMR tubes are not biodegradable, but have lumens therethrough with side holes along the tube length, providing access to the myocardium from with the lumen. The non-biodegradable tube can be formed from a metal, polymer or other bio-stable material. The nonbiodegradable tubes are preferably coated with and contain releasable angiogenic material, promoting new vessel growth along the length of the tube, where the new vessels may be supplied with blood through the tube side holes. One method utilizes PMR tubes implanted into the myocardium from outside the heart and can be performed during open heart surgery or during a minimally invasive procedure. In one embodiment, a growth factor may be infused in a slow release polymer. The growth factor or drug and polymer can be placed in a tube having side poles for drug release. By placing the growth factor or drug in the polymer the growth factor or drug can be slowly released into the myocardium after implantation of the tube therein. In one embodiment of the tube containing the growth factor or drug and slow release polymer, the tube includes side holes and sealed ends.
Another set of methods according to the present invention involves injecting angiogenic material into the myocardium. A preferred method includes creating small bore holes or direct needle injection, for example using micro needles, into the myocardium utilizing a catheter within the heart. In the case of hole creation, a fluid, gel, polymer (biodegradable or biostable) or adhesive carrying an angiogenic material is injected into the hole. As the angiogenic substance is absorbed into the myocardium, in one method, a patent hole remains surrounded by myocardial tissue treated with angiogenic material. In another method, the injection hole closes, leaving no patent hole. New vessel growth is promoted by both the healing response to the wound and by the angiogenic substance. Blood circulation to myocardial tissue is increased by both the presence of the patent hole and the presence of new blood vessels supplied by existing coronary vessels and the heart interior. An alternative method utilizes angiogenic material injected into the myocardium from the exterior of the heart, in conjunction with open heart surgery or during a minimally invasive procedure.
In yet another alternate method, angiogenic materials delivered to the heart to promote new vessel growth. The new vessel growth is the consequence of the angiogenic material, for example, growth factor and any tissue reaction such as inflammation, rather than wounding the tissue.
Yet another set of methods includes externally wounding the heart and applying an external patch containing an angiogenic substance to the wound. The wound preferably penetrates into the myocardium. The healing response, enhanced by the angiogenic material, promotes new vessel growth near the wound. While the wound does not normally penetrate through to the heart chamber interior, new vessel formation can reach the chamber interior and also connect with pre-existing vessels in healthy heart muscle. A wound or series of wounds extending from healthy into hibernating tissue can create a network of vessels from healthy into hibernating tissue, supplying the hibernating tissue with blood. In another method, an external patch containing angiogenic material is applied to the heart without significant injury to the heart.
Any therapeutic agent, including small molecular drugs, proteins, genes and cells which could promote angiogenesis, protect tissues (i.e., cardiac protection), or promote tissue regeneration including Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth Factors (FGFs) is believed to be suitable for use with present invention. Carriers for the therapeutic agents of the present invention include polymers and angiopoietins including biodegradable and biostable hydrogels, and dissoluble polymers. Adhesives suitable for binding the present invention include fibrin glues and cyanoacrylates.
The injection of therapeutic agents and implantation of implants such as tubes for the placement of patches, is believed to have application to the treatment of other forms of heart disease in addition to the context of percutaneous myocardial revascularization. Some of these diseases include, for example, heart failure, myocardial infarction, and cancers, for example of the bladder, liver and kidneys.
Referring now to the drawings wherein like reference numerals indicate like elements throughout the several views, a human heart 20 having an aorta 22, a left ventricle 30, and a myocardium 28 is illustrated in
After degradation of the biodegradable material, holes 32 can remain patent while the angiogenic material has promoted blood vessel growth near the hole walls and into the myocardium. Holes 32 can also close, leaving no patent hole but leaving newly formed blood vessels. The inventors believe the new vessel growth will be significantly enhanced by the angiogenic substance, thereby increasing blood flow from inside the left ventricle to the myocardium of the left ventricle. New vessel growth is expected to join with other vessels at anastomoses, forming a larger network of blood vessels in the myocardium supplied by blood from the left ventricle and blood from other vessels supplied by coronary arteries. Preferred substances for encouraging tissue growth of ischemic tissue include Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), PDGF, angiopoietins (Ang1, Ang2), estrogen or genes effecting the production of growth factors such as MCP-1 and HIFI-α, DEL-1, Tat, and Akt.
Catheter 24 can be used to treat heart failure and the heart after myocardial infarction by directly injecting agents or implants into the diseased myocardium. Agents for treating heart failure include positive inotropic agents, diuretics, vasodilators, neurohormonal antagonists, calcium channel blockers, anti-ischemic agents, antiarrhythmics, anticoagulants; and natruiretic peptides, such as BNP, endothelian, growth hormone, and adenosine receptor antagonists. Survival genes or proteins may be used to treat heart tissue following myocardial infarction. These include, for example, AKT kinases, cyclases, i.e., adenylyl cyclase VI, IkB, or any anti-apoptotic molecule or protein, or other molecules which aid in heart muscle regeneration, such as the angiogenesis inducing agents listed above.
Catheter 24 can be used to treat cancers by injecting agents or implants into solid tumors or cancerous tissues, which are accessible endoluminally. Such agents for treatment of cancers include, for example, cytoxic proteins, such as FASL and TK/gancyclovir; or cytostatic agents, such as Rb or p53, or the genes encoding these proteins. Anti-angiogenic molecules can also be injected to treat cancer; these include, for example, endostatin, angiostatin, thrombospondin, dox-RGD, antibodies to or small molecule inhibitors of VEGF and other endogenous angiogenic molecules or other small molecules such as paclitaxel, 5-FU, etc.
Similarly to the substance for encouraging tissue growth used for the PMR treatment, the agents used to treat heart failure and the heart after myocardial infarction, as well as the agents used to treat cancer, can be incorporated into a carrier material. This material is preferably biodegradable or dissoluble but can be substantially bio-stable or non-biodegradable. The carrier material preferably holds the therapeutic agents in proximity to the tissue to be treated.
Such carriers can include, among others, biodegradable polymers suitable for use in the present invention include: poly(L-lactide) (PLLA), poly(D,L-lactide) (PLA), poly(glycolide) (PGA), poly(L-lactide-co-D.L. Lactide) (PLLA/PLA), poly(L-lactide-coglycolide) (PLA/PGA), poly(glycolide-co-trimethylene carbonate) (PGA/PTMC), polydioxanone (PDS), polycaprolactone(PCL), polyhydroxybutyrate (PHBT), poly(phosphazenes), poly(D,L-lactide-co-caprolactone) (PLA/PCL), poly(glycolide-cocaprolactone) (PGA/PCL), poly(phosphase ester) and polyanhydrides. Other materials suitable for mixing with growth factors include, for example: hydrogels, polyethylene oxide and its copolymers, polyvinylpyrolidone, polyacrylates, polyesters, gelatins, collagens, proteins, alginates, karaya gum, guar gum, agar, algin, carrageenans, pectins, xanthan, starch based gums, hydroxyalkyl and ethyl ethers of cellulose, sodium carboxymethyl cellulose, polyvinyl alcohol, and polyurethanes.
Proximal shaft 44 is preferably formed from a stainless steel hypotube which is more rigid than distal. shaft 46. Shaft 44 defines a lumen 56 extending longitudinally therethrough. Proximal shaft 44 preferably extends the substantial majority of the length of inner shaft 38, to enhance the pushability and torqueability of inner shaft 38. It should be understood that although hypotube construction is preferred for proximal shaft 44, shaft 44 could be formed in the same manner as distal shaft 46 as described in more detail below or from another sufficiently torqueable and pushable construction as known in the art.
Distal shaft portion 46 is preferably more flexible than proximal shaft 44 to enhance trackability of inner shaft 38 proximate cutting tip 40. Distal shaft 46 can be formed from a helical coil 58 defining an elongate lumen 60 therethrough in fluid communication with lumen 56 of proximal shaft 44 and lumen 52 of cutting tip 40. Coil 58 can be surrounded by a polymer sheath 62. Sheath 62 may be PTFE, a shrink wrap or other similar biocompatible material known to those skilled in the art. The inside coil 58 forming the lumen wall of lumen 60 can be similarly coated. Shaft 46 can also be formed from an elastic alloy such as Nitinol.
Tip 40 and proximal shaft 44 can be connected to distal shaft 46 by two short tubular segments 64 and inserted within lumens 56 and 60, and 56 and 52, respectively. Tubular segments 64 can be small diameter hypotube segments or other sufficiently durable and biocompatible tubular members defining lumens in fluid communication with lumens 52, 56 and 60. An adhesive, braze or swage can be used to attach segments 64 to shafts 44 and 46 and tip 40.
In use, cutting tip 40 of inner shaft 38 can be delivered intravascularly to the heart wall and myocardium. by a catheter tube or tubes. In one embodiment, once cutting tip 40 has been. brought into contact with the heart wall, motor 48 can be activated to rotate cutting tip 40 and consequently blade 42. By further advancing cutting tip 40 into the myocardium of the heart, tissue in the path of the rotating blade will disintegrate. The disintegrated tissue can be aspirated through the lumen 52 extending through inner shaft 38. It can be appreciated that cutting tip 40 can penetrate the myocardium without being rotated. However, disintegration of tissue will generally not occur without rotating of tip 40.
Generally, the hole depth is preferably between ⅓ and � the thickness of the heart wall. The hole, however, could completely penetrate the myocardium for delivery of therapeutic agents to the pericardial space. The specific hole depth is determined on a case by case basis for each patient. Ultrasonic techniques may be used to view the patient's heart to determine the appropriate depth of the holes. In one method, radiopaque or contrast material is injected into the hole, in part to determine hole depth. A hole can be cut or formed, followed by radiopaque material injection and hole depth visualization using a method such as fluoroscopy. The cutting, radiopaque injection, and depth visualization cycle can be repeated until the desired hole depth is achieved. The depth of the holes will be generally proportional to the depth of penetration of cutting tip 40 into the myocardium. The rotation rate of cutting tip 40 may vary upon the character of the heart tissue encountered but should be rapid enough to disintegrate the tissue in the path of the cutting tip. The imaging agent can be incorporated into or mixed with a growth factor drug.
Inner shaft 38 and lumen 52 can be used to deliver angiogenic substances and adhesives and other carriers within the myocardium while tip 40 is still in place. In a preferred method, adhesives cure after leaving the tip. One method uses moisture cured adhesives. Once the angiogenic material has adhered to the walls of the hole bored into the myocardium., the angiogenic substance is more likely to remain in place within the myocardium. Adhesives preferably bind angiogenic material to the hole walls with a strength sufficient to resist immediate expulsion from the hole while being degradable or absorbable so as to allow diffusion of angiogenic material from the adhesive and absorption of angiogenic material into the myocardium. Inclusion of a fluoroscopic agent or radiopaque material with the angiogenic material can aid in visualizing expelled material.
Referring now to
A preferred embodiment tube has a circular cross section, a lumen 70, side holes 74, proximal port 80 and distal port 68, allowing blood flow through proximal port 80, lumen 70, side holes 74, distal port 68 and into myocardial tissue. Tube 66 is preferably formed of a biodegradable polymeric material, discussed further below. One embodiment has tubular walls porous to blood passage rather than larger, discrete holes. Another embodiment has no lumen and is formed of time-released therapeutics embedded in biodegradable material, such that the angiogenic substance is delivered within the myocardial tissue and the tube dissolves, possibly leaving a patent hole surrounded by tissue treated with angiogenic substance. While the preferred tube embodiment has a round cross-section, other embodiments have triangular, square, and elongate rectangular cross sections. Tube 66 preferably has a cutting tip 72 for easing insertion into the myocardium. Tubes can also have barbed outer surfaces to aid in retaining the spike within the myocardium. The tube can include radiopaque material or contrast as an aid in visualizing fluoroscopically where tubes have already been implanted. The tubes can be implanted in a pattern, leading from healthy tissue to hibernating tissue, creating a network of new blood vessels carrying both blood supplied from coronary arteries and the heart chamber itself.
The tube can be delivered through the lumen of a catheter from within a heart chamber. Tubes can also be delivered externally into the myocardium, either during open heart surgery or during a minimally invasive procedure. Tubes delivered externally preferably have lumens, side holes, closed proximal ends to minimize blood loss, and outside surface barbs to lessen the risk of the tube being expelled from the heart muscle. In a minimally invasive procedure, the PMR tubes can be injected through an elongate catheter into the pericardium. The PMR tubes can be injected entirely through the myocardium or can stop short of such penetration. The inventors believe the externally inserted PMR tubes can significantly promote vascularization within the myocardium, even where the PMR tubes do not penetrate through to the endocardium.
Although tubes 66 have been described herein with respect to PMR, it is anticipated that the tubes can be used for the treatment of heart failure and the heart after myocardial infarction by incorporating the therapeutic agents described above with respect to these conditions. It is also believed that the tubes could be used for treating cancer by incorporating the therapeutic agents described above.
Tubes 92 and 93 should be long enough and flexible enough to be advanced intraluminally to a desired body organ such as the heart, liver, bladder, or kidneys. The diameter of tube 92 should be sufficiently small to be advanced through the desired body lumen. Tubes 92 and 93 can be formed from biocompatible polymers or other materials known to those skilled in the art. Tubes 97 and 98 can be adhered to tubes 92 and 93 respectively by materials known to those skilled in the art. Tubes 97 and 98 can be hypotubes made from a metallic material or from a sufficiently rigid polymer or other material that they can be advanced into tissue for fluid injection therein.
As an alternative to the tubular implants described above, catheter 91 can be used to form an in situ implant. For example, a polymer could be pre-mixed with any of the therapeutic agents described above for treatment of the heart, liver, kidneys, bladder or other organs and solid tumors. The polymer pre-mix could be infused through, for example, lumen 94 into a tissue to be treated. At the same location a cross-linking agent could be infused through lumen 95 into the tissue. This would result in the polymer becoming cross-linked and solidifying in tissue. The cross-linking agent can also be mixed into a contrast solution such that the implants would become radiopaque. An example polymer to be pre-mixed with the therapeutic agent is alginate polymer, which can be cross-linked by multivalent ions. In another example, the polymer, if a polycation, gelatin, chitosan or the like which can be delivered through one lumen and the therapeutic agent if a polyanion such as DNA can be delivered through the second lumen. A polyelectrolyte complex will be formed when the polycation mixes with the polyanion, forming a solid material.
The polymer can be bio-stable or biodegradable, including dissoluble polymers. After the implants are placed in the tissue, the therapeutic agent is slowly released. The rate of release of the therapeutic agent to the surrounding tissue may be controlled by, for example, 1) diffusion of the agent through the polymer implant if the polymer implant is bio-stable; 2) by the rate of polymer degradation or dissolution if the implant is made of a biodegradable or dissolvable implant; or 3) by the rate of ion exchange if the implant is formed using two oppositely changed polyelectrolytes. In this manner, therapeutic agents may be delivered to tissue over periods of days, weeks, or a longer period of time.
An alternate embodiment of an implant which can be injected through a single lumen catheter such as that shown in
Referring now to
Patch 90 is preferably biodegradable, capable of being absorbed by the body after it is no longer needed. One patch includes a reservoir of angiogenic substance that leaches out the inside of the patch, supplying more wound healing and angiogenic compound over time.
Externally wounding the heart and applying a patch can be performed in conjunction with open heart surgery, where the heart is available for such a procedure. Minimally invasive procedures can also be used to access the heart for externally wounding the heart, creating wound and applying patch through a relatively small opening. Applicants believe externally wounding the heart triggers a healing response within the myocardium, including the formation of new blood vessels to the wounded area. While the incisions preferably do not penetrate through the entire thickness of the chamber wall, applicants believe the incisions within the myocardium trigger new blood vessel growth within the myocardium which can be supplied by vessels within the heart chamber or by other coronary vessels. While it is believed to be preferable to wound the tissue prior to placement of the patch, the patch is believed to have therapeutic value as well when placed on tissue that has not been wounded.
A variety of angiogenic substances and growth factors can be used in accordance with the present invention. Growth factors such as Fibroblast Growth Factor (FGF, FGF-1, FGF-2), Vascular Endothelial Growth Factors (VEGF) (all constructs including VEGF-2) and Endothelial Mitogenic Growth Factors are among the growth factors preferred for use with the present invention. Angiogenic substances such as estrogen, including estradiol (E2), estriol (E3) and 17-Beta Estradiol are also believed suitable for use with the present invention. Estrogen is believed to induce angiogenesis and increase permeability. This provides increased local blood circulation through neovascularization. Gene transfer into the heart tissue can be done as well.
The therapeutic agents used in the present invention also include, for example, pharmaceutically active compounds, proteins, oligonucleotides, ribozymes, anti-sense genes, DNA compacting agents, gene/vector systems (i.e., anything that allows for the uptake and expression of nucleic acids), nucleic acids (including, for example, recombinant nucleic acids; naked DNA, cDNA, RNA; DNA, cDNA or RNA in a noninfectious vector or in a viral vector which may have attached peptide targeting sequences; antisense nucleic acid (RNA or DNA); and DNA chimeras which include gene sequences and encoding for ferry proteins such as membrane translocating sequences ("MTS") and herpes simplex virus-1 ("VP22"), and viral liposomes and cationic polymers that are selected from a number of types depending on the desired application. For example, biologically active solutes include anti-thrombogenic agents such as heparin, heparin derivatives, urokinase, PPACK (dextrophenylalanine proline arginine chloromethylketone), rapamycin, probucol, and verapamil; angiogenic and anti-angiogenic agents; anti-proliferative agents such as enoxaprin, angiopeptin, or monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid; anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine; antineoplastic/antiproliferative/anti-mitotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors; anesthetic agents such as lidocaine, bupivacaine, and ropivacaine; anticoagulants such as D-Phe-Pro-Arg chloromethyl ketone, an RGD peptide-containing compounds, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet factors; vascular cell growth promoters such as growth factors, growth factor receptor antagonists, transcriptional activators, and translational promoters; vascular cell growth inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; cholesterol-lowering agents; vasodilating agents; agents which interfere with endogenous vascoactive mechanisms, and combinations thereof. Cells of human origin can be used (autologous or allogeneic) or from an animal source (xenogeneic), genetically engineered if desired to deliver proteins of interest at the transplant site. The delivery media can be formulated as needed to maintain cell function and viability.
Polynucleotide sequences useful in the practice of the present invention include DNA or RNA sequences having a therapeutic effect after being taken up by a cell. Examples of therapeutic polynucleotides include anti-sense DNA and RNA; DNA coding for an antisense RNA; or DNA coding for tRNA or rRNA to replace defective or deficient endogenous molecules. The polynucleotides of the invention can also code for therapeutic peptides. A polypeptide is understood to be any translation product of a polynucleotide regardless of size, and whether glycosylated or not. Therapeutic polypeptides include as a primary example, those polypeptides that can compensate for defective or deficient species in an animal, or those that act through toxic effects to limit or remove harmful cells from the body. In addition, the polypeptides or proteins that can used include without limitation, angiogenic factors including acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor α and β, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α, hepatocyte growth factor and insulin-like growth factor; growth factors; cell cycle inhibitors including CDK inhibitors; thymidine kinase ("TK") and other agents useful for interfering with cell proliferation, including agents for treating malignancies; and combinations thereof. Still other useful factors, which can be provided as polypeptides or as DNA encoding these polypeptides, include monocyte chemoattractant protein ("MCP-1"), and the family of bone morphogenic proteins ("BWPs"). The known proteins include BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. Currently preferred BMPs are any of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7. These dimeric proteins can be provided as homodimers, heterodimers, or combinations thereof, alone or together with other molecules. Alternatively or, in addition, molecules capable of inducing an upstream or downstream effect of a DMP can be provided. Such molecules include any of the "hedgehog" proteins, or the DNAs encoding them.
In one exemplary embodiment of the present invention, the medical device has recombinant nucleic acid incorporated therein, wherein the recombinant nucleic acid comprises a viral vector having linked thereto an exogenous nucleic acid sequence. "Exogenous nucleic acid sequence" is used herein to mean a sequence of nucleic acids that is exogenous to the virus from which the vector is derived. The concentration of the viral vector, preferably an adenoviral vector, is at least about 1010 plaque forming units ("p.f.u."), preferably at least about 1011, p.f.u. Alternatively, the concentration of the viral vector is limited by the concentration that results in an undesirable immune response from a patient.
A variety of adhesives are suitable for the present invention, both for adhering a patch over a heart wound, and for retaining angiogenic material within a wound. Biodegradable polymer and materials are suitable for mixing with the therapeutic agents as described with respect to the other embodiments above. One adhesive is a hydrogel composed of gelatin and poly(L-glutamic acid)(PLGA). The hydrogel is formed by chemically cross linking gelatin and poly(L-glutamic acid). Another adhesive is fibrin glue. One suitable fibrin glue includes fibrinogen, thrombin, calcium chloride and factor VIII. Another family of adhesives is cyanoacrylates. Preferred cyanoacrylates include butyl-2-cyanoacrylate (Histoacryl), ethyl-2-cyanoacrylate, and octyl-2-cyanoacrylate. Gelatin-resorcinol formaldehyde-glutaraldehyde is another suitable adhesive.
Applicants believe many polymers having suitable adhesive properties can also be utilized, including without limitation: polyurethanes having amino groups, di- and trifunctional diols; polyvinyl acetates; polyamides; polyvinyl alcohols; polystyrenes; polylactides; polylactones; block co-polymers including polyesters, polyamides, and polyurethanes; and combinations and mixtures thereof.
Growth factors, angiogenic substances and biodegradable carriers and adhesives can be applied internally to punctures within heart chamber walls, externally to external heart wounds, and incorporated into tubes or spikes for implantation into the myocardium or other organs or solid tumors.
It is anticipated that the patch of the present invention can be used to treat heart failure, heart tissue following myocardial infarction and cancers, in addition to ischemic tissue. In each instance, the therapeutic agents described above with respect to those conditions could be incorporated into the patch for delivery to the tissue. In the case of heart failure, the treatment of heart tissue following myocardial infarction and the treatment of cancer, it is believed that the patch would be placed directly on, or in close proximity to the tissue to be treated.
Gun 112 includes a body 116. Slidably disposed within body 116 and schematically shown in
Catheter 114 includes an inner tubular shaft 126. Inner tubular shaft 126 includes a sharpened distal end 127. Like syringe 118, slider 120 and plunger 124, inner shaft 126 can be moved proximally or distally as shown by the arrows. More particularly, inner shaft 126 can be moved from a proximal position A wherein tip 127 is disposed within an outer shaft 129 of catheter 114 to a second position B, wherein tip 127 is disposed distally of outer shaft 129.
Syringe 118 includes an inner chamber 130 for containing a dosage of a drug or other fluid. Disposed at the distal end of plunger 124 is a plunger seal 132. Syringe 118 including plunger seal 132 preferably are prepacked to contain a quantity of drug, agent or other fluid prior to placement in gun 112. Syringe 118 includes a Luer fitting 128 or similar attachment device to fluidly connect inner shaft 126 to syringe 118. The proximal ends of plunger 124 includes a handle 134. Handle 134 can be used to rotate plunger 124 about its longitudinal axis within housing 116. Plunger 124 includes a plurality of teeth 136 extending therefrom. Syringe 118 also includes a cradle 138 in which is disposed a one-way plunger lock 140 which is biased toward plunger 124 by spring 142. Lock 140 includes one or more teeth having a slope which allows teeth 136 of plunger 124 to be advanced distally thereover, but engages with teeth 136 to prevent plunger 124 from being withdrawn proximally. Plunger 124 can, however, be withdrawn proximally if it is rotated about its longitudinal axis by using handle 134 such that teeth 136 are disposed away from lock 140, for example, pointed upward rather than downward as shown in
Slider 120 includes a syringe restraint member 144 which includes a surface engageable with cradle 138 of syringe 118. A plunger advancing member 146 is pivotally attached to slider 120 by pin 148. A spring 150 biases advancing member 146 toward a vertical position as shown in
Catheter 114 includes a preferably radiopaque, atraumatic hood 163 at its distal end and a manifold 164 at its proximal end. Manifold 164 includes a port 166 for infusion or withdrawal of fluids from catheter 114 through a lumen defined between inner shaft 126 and outer shaft 129. Manifold 164 also includes a flange 168 engageable with a portion of body 116 to connect body 116 to catheter 114.
It can be appreciated by those skilled in the art that there are numerous materials which can be advantageously used to construct the apparatus disclosed herein. These materials should be selected in view of the use to which the apparatus is put.
In use, catheter 114 can be advanced into a chamber of the heart, for example, the left ventricle through a femoral, brachial or carotid artery approach similar to catheter 24 of
Substantially simultaneously with the advancement of tip 127 from position A to position B, plunger advancing member 146 will engage the proximal side of one of the teeth 136 and advance plunger 136 distally into reservoir 130 to advance a dosage of drug or growth factor through inner shaft 126 and out tip 127 which, in position B would be disposed within the myocardium. The amount of the dosage can be regulated by limiting the travel of trigger 122 by adjusting screw 160. It can be appreciated that ring 182 should limit the travel in the distal direction of inner shaft 126 and syringe 118 to a distance less than the distal travel of plunger 124 such that there can be relative advancement of plunger 124 into chamber 130 to advance drug or growth factor through inner shaft 126.
When trigger 122 is released, it will pivot in a counterclockwise direction back to the position shown in
Marker 200 can be used for mapping purposes, for example, to define a target zone or perimeter for subsequent PMR treatment. Marker 200 can also be used chronically for future PMR treatments, diagnosis and monitoring. Marker 200 can also be coated or impregnated with a growth factor, drug or other therapeutic agent.
Manifold 264 includes a flange 302 which could be used to engage a portion of gun body 116 in a manner similar to that of flange 168 of manifold 164 described above. Within manifold 262 includes a plurality of steps 304, 305 and 306 disposed therein. Disposed proximate the proximal end of proximal portion 190 of inner shaft 126 is an alternate embodiment of a Luer fitting 274, which can engage Luer fitting 128 of syringe 118 of gun 116. Luer fitting 274 includes threads 272. At the distal end of Luer fitting 274 is a step engaging member 300. A spring 278 is fixed at its proximal end within manifold 274 and at its distal end to Luer fitting 274. Spring 278 is biased to draw Luer fitting 274 distally.
It can be appreciated that the further engaging member 300 advances distally, the farther inner shaft 126 and thus distal tip 227 will advance distally. Thus, using manifold 264 and Luer fitting 274, the depth of penetration into the heart wall of tip 227 can be controlled. It is, in fact, contemplated that the depth of penetration could be adjusted such that tip 222 would completely penetrate the heart wall to dispose tip 227 between the epicardium and the pericardial. sac. If tip 227 is disposed in such a location, catheter 114 could be used to deliver drugs, growth factors or other therapeutic agents or fluids within the pericardial sac.
It can be appreciated that the distal movement of inner shaft 126 can be limited by steps 304, 305 or 306 or manifold 264, by configuration as shown with respect to manifold 164 above, or by swage 196 engaging hood 163 as shown in
Slidably disposed within housing 352 is a fitting 366 which can be a Luer fitting having threads 368. Fitting 366 is slidable proximally and distally in the direction shown by the arrows. Fitting 366 is preferably connected at its distal end to inner shaft 126 and preferably defines a lumen 174 extending therethrough in fluid communication with the lumen through inner shaft 126. The catch arm 370 extends in a distal direction to its distal end 372. Fitting 366 is preferably formed from a polymer or other material known to those skilled in the art. The material from which catch arm 370 is formed is preferably elastic enough that arm 370 can be pressed inwardly toward groove 356.
A helical spring coil 376 is preferably disposed around a portion of inner shaft 126. Spring 376 has a proximal end and a distal end. The proximal end of spring 376 is connected to the distal end of fitting 366 and the distal end of spring 376 is connected to an anchor 378 extending from housing 352. As shown in
Numerous characteristics and advantages of the invention covered by this document have been set forth in the foregoing description. It will be understood, however, that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of parts without exceeding the scope of the invention. The invention's scope is, of course, defined in the language in which the appended claims are expressed.
|Cited Patent
|Filing date
|Publication date
|Jun 23, 1986
|Jul 26, 1988
|Collagen Corporation
|Wound-healing composition
|Jan 20, 1987
|Dec 13, 1988
|Ruiz Oscar F
|Radio frequency angioplasty catheter system
|Aug 1, 1988
|Jan 30, 1990
|C. R. Bard, Inc.
|Catheter with contoured ablation electrode
|Jul 2, 1990
|Sep 10, 1991
|Everest Medical Corporation
|Electrosurgical implement for tunneling through tissue
|Oct 30, 1990
|Mar 3, 1992
|Advanced Cardiovascular Systems
|Optical fiber lasing apparatus lens
|Nov 24, 1992
|Nov 16, 1993
|Boston Scientific Corporation
|Injection therapy catheter
|Oct 30, 1992
|Feb 22, 1994
|Wilk Peter J
|Coronary artery by-pass method and associated catheter
|Aug 16, 1993
|Oct 25, 1994
|Schneider (Usa) Inc.
|Cutter for atherectomy catheter
|Dec 30, 1993
|Nov 15, 1994
|Heart Technology, Inc.
|Tissue dissipative recanalization catheter
|Feb 2, 1993
|Dec 6, 1994
|Vidamed, Inc.
|Medical probe device and method
|Jun 16, 1993
|Jan 10, 1995
|Advanced Cardiovascular Systems, Inc.
|Method for intra-operative myocardial device revascularization
|Feb 25, 1993
|Feb 14, 1995
|Advanced Cardiovascular Systems
|System and method for percutaneous myocardial revascularization
|Mar 29, 1993
|Apr 4, 1995
|Boston Scientific Corporation
|Electro-coagulation and ablation and other electrotherapeutic treatments of body tissue
|Aug 27, 1993
|Apr 11, 1995
|Medtronic, Inc.
|Method and apparatus for ablation
|Aug 27, 1993
|Jul 11, 1995
|Medtronic, Inc.
|Method and apparatus for R-F ablation
|Mar 25, 1994
|Dec 12, 1995
|Micromedics, Inc.
|Fluid separation control attachment for physiologic glue applicator
|Aug 9, 1994
|Jun 4, 1996
|Durgin, Jr.; Russell F.
|Integrated catheter for diverse in situ tissue therapy
|Jun 7, 1993
|Aug 27, 1996
|Yoon; Inbae
|Safety penetrating instrument
|Feb 13, 1995
|Sep 3, 1996
|Altman; Peter A.
|Implantable device for the effective elimination of cardiac arrhythmogenic sites
|Mar 31, 1995
|Oct 29, 1996
|Baxter International Inc.
|Methods for enhancing vascularization of implant devices
|Nov 9, 1994
|Jan 7, 1997
|Taheri; Syde A.
|Transcavitary myocardial perfusion apparatus
|Jan 9, 1995
|Jan 14, 1997
|Osypka; Peter
|Fiber optic endoscope
|May 9, 1994
|Mar 4, 1997
|Decker; Rand A.
|Surgical insertion device and method
|Apr 8, 1994
|Apr 15, 1997
|Campbell, Jr.; Robert M.
|Apparatus and method for effecting surgical incision through use of a fluid jet
|Dec 22, 1995
|May 6, 1997
|Applied Medical Resources Corporation
|T-anchor suturing device and method for using same
|Jan 16, 1996
|Sep 30, 1997
|Rita Medical Systems, Inc.
|Multiple antenna ablation apparatus and method
|Nov 28, 1994
|Oct 28, 1997
|Stuart D. Edwards
|Ablation apparatus for cardiac chambers
|Nov 22, 1995
|Nov 4, 1997
|Arthrocare Corporation
|System and method for electrosurgical tissue canalization
|Nov 22, 1995
|Dec 16, 1997
|Arthrocare Corporation
|System and method for electrosurgical cutting and ablation
|Oct 10, 1995
|Dec 23, 1997
|Plc Medical Systems, Inc.
|Thoracoscopic transmyocardial revascularization handpiece assembly
|Feb 27, 1996
|Feb 3, 1998
|Murphy-Chutorian; Douglas
|Combined mechanical/optical system for transmyocardial revascularization
|Mar 29, 1996
|Mar 10, 1998
|Eclipse Surgical Technologies, Inc.
|Depth stop apparatus and method for laser-assisted transmyocardial revascularization and other surgical applications
|Mar 29, 1996
|Mar 10, 1998
|Mueller; Richard L.
|Lateral-and posterior-aspect method and apparatus for laser-assisted transmyocardial revascularization and other surgical applications
|Jun 7, 1995
|Sep 15, 1998
|The Trustees Of Columbia University In The City Of New York
|Myocardial revascularization through the endocardial surface using a laser
|Nov 7, 1996
|Sep 22, 1998
|Myocardial Stents, Inc.
|Device and method for trans myocardial revascularization (TMR)
|Sep 18, 1995
|Nov 10, 1998
|Y. Pierre Gobin
|Component mixing catheter
|Aug 21, 1997
|Feb 2, 1999
|Scimed Life Systems, Inc.
|Local delivery of estrogen for angiogenesis
|Sep 13, 1996
|Feb 16, 1999
|Eclipse Surgical Technologies, Inc.
|Method and apparatus for mechanical transmyocardial revascularization of the heart
|Mar 6, 1997
|Oct 19, 1999
|Scimed Life Systems, Inc.
|Transmyocardial revascularization catheter and method
|Nov 8, 1996
|Nov 9, 1999
|St. Elizabeth's Medical Center Of Boston
|Methods for enhancing angiogenesis with endothelial progenitor cells
|Feb 1, 1999
|Feb 22, 2000
|Meadox Medicals, Inc.
|Bioresorbable compositions for implantable prostheses
|Nov 8, 1996
|Mar 28, 2000
|Thomas J. Fogarty
|Transvascular TMR device and method
|Nov 2, 1998
|Apr 4, 2000
|Scimed Life Systems, Inc.
|Percutaneous myocardial revascularization growth factor mediums and method
|Mar 18, 1997
|Apr 25, 2000
|Thomas J. Fogarty
|Transvascular TMR device and method
|Apr 29, 1999
|Apr 25, 2000
|Hussein; Hany
|Device and method for trans myocardial revascularization
|May 6, 1997
|May 2, 2000
|Eclipse Surgical Technologies, Inc.
|Revascularization with laser outputs
|Mar 5, 1998
|May 2, 2000
|Scimed Life Systems, Inc.
|Percutaneous myocardial revascularization device and method
|Feb 27, 1996
|Aug 8, 2000
|The Regents Of The University Of California
|Gene therapies for enhancing cardiac function
|Dec 8, 1997
|Nov 28, 2000
|Heartport, Inc.
|Method for delivery of therapeutic agents to the heart
|Dec 18, 1998
|Jan 23, 2001
|Eclipse Surgical Technologies, Inc
|Resistive heating system and apparatus for improving blood flow in the heart
|Oct 5, 1995
|Apr 10, 1997
|Sievers Hans Hinrich Prof Dr M
|Catheter for transmyocardial revasculation with guidable multi=ID main catheter
|May 24, 1996
|Aug 29, 1996
|P Osypka Mbh Ges Fuer Medizint
|Vorrichtung zum Perforieren der Herzwand
|Jun 23, 1995
|Jan 4, 1996
|Cormedics Corp.
|Vascular treatment method and apparatus
|May 9, 1996
|Nov 14, 1996
|Cardiogenesis Corporation
|System for treating or diagnosing heart tissue
|May 31, 1996
|Dec 19, 1996
|Indiana University Foundation
|Pericardial therapeutic and diagnostic agent delivery
|Jun 7, 1996
|Dec 19, 1996
|Abela Laser Systems, Inc.
|Optical fiber catheter and method
|Nov 22, 1996
|May 29, 1997
|Arthrocare Corporation
|Systems and methods for electrosurgical myocardial revascularization
|Nov 22, 1996
|Jul 3, 1997
|Localmed, Inc.
|Localized intravascular delivery of growth factors for promotion of angiogenesis
|Feb 20, 1997
|Aug 21, 1997
|Percutaneous endomyocardial revascularization
|Mar 3, 1997
|Sep 12, 1997
|Energy Life Systems Corporation
|Device and method for trans myocardial revascularization
|May 20, 1997
|Nov 27, 1997
|Amnon Sudai
|Apparatus and methods for revascularization and perfusion
|Aug 7, 1997
|Feb 12, 1998
|Localmed, Inc.
|Transmural drug delivery method and apparatus
|Oct 16, 1997
|Apr 23, 1998
|Ethicon Endo-Surgery, Inc.
|Methods and devices for improving blood flow to the heart of a patient
|Oct 20, 1997
|Apr 30, 1998
|Plc Medical Systems, Inc.
|Percutaneous transmyocardial revascularization marking system
|Apr 1, 1998
|Oct 15, 1998
|MAX-PLANCK-Gesellschaft zur F�rderung der Wissenschaften e.V.
|Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
|Dec 4, 1998
|Jun 17, 1999
|Heartport, Inc.
|Method and apparatus for delivery of therapeutic agents to the heart
|Sep 10, 1999
|Mar 23, 2000
|Percardia, Inc.
|Transmyocardial shunt for left ventricular revascularization
|Jul 19, 1999
|Mar 30, 2000
|Ekos Corporation
|Ultrasound catheter for improving blood flow to the heart
|Nov 11, 1999
|Jun 22, 2000
|Tre Esse Progettazione Biomedica S.R.L.
|Catheter system for performing intramyocardiac therapeutic treatment
|Jul 28, 2000
|Feb 8, 2001
|C.R. Bard, Inc.
|Catheter positioning systems
|Article entitled "Gene therapy improves leg circulation-next step heart?", 70th Scientific Sessions, published on or before Nov. 2, 1998, 2 pages.
|Article entitled "Gene therapy improves leg circulation—next step heart?", 70th Scientific Sessions, published on or before Nov. 2, 1998, 2 pages.
|Canadian Patent Office, Examination Report in related Canadian patent application No. 2307102, dated Feb. 22, 2006.
|European Patent Office, Examination Report in related EP application No. 01270107.4, mailed May 18, 2005.
|European Search Report, Appln. No. EP 98 95 7545, (Aug. 23, 2000).
|Gal et al., Abstract entitled "Analysis of Photoproducts Free Radicals and Particulate Debris Generated . . . ", Lasers in Surgery and Medicine, 11(2) 1991, 1 page.
|Goldman et al., "Nonoperative Portacaval Shunt in Swine", Investigative Radiology, vol. 25, No. 5, May 1990, 5 pages.
|Hershey et al., "Transmyocardial Puncture Revascularization", Geriatrics, Mar. 1969, pp. 101-108.
|International Search Report, PCT/US 01/42994, (Nov. 7, 2001).
|Isner, J., Abstract entitled "Right Ventricular Myocardial Infarction", JAMA, v259, n5, Feb. 5, 1988, 12 pages.
|Japan Patent Office, Notification of Reasons for Refusal in related Japanese Patent Application No. 2000-518598, mailed Apr. 8, 2008.
|Japan Patent Office, Notification of Reasons for Refusal in related Japanese Patent Application No. 2000-518598, mailed Jun. 5, 2007.
|Khazei et al., "Myocardial Canalization", The Annals of Thoracic Surgery, vol. 6, No. 2, Aug. 1968, pp. 163-171.
|Kolata, G., "Gene Therapy Gives Blood a Path Around Leg Blockages, Researchers Say", The New York Times, Nov. 10, 1992 2 pages.
|Mack et al., "Cardiopulmonary Support and Physiology", The Journal of Thoracic and Cardiovascular Surgery, vol. 115, No. 1, Jan. 1998, 10 pages.
|Mirhoseini et al., Abstract entitled "Transventricular Revascularization by Laser", Lasers in Sugery and Medicine, 2(2), 1982, 1 page.
|Pickering et al., Abstract entitled "Proliferative Activity in Peripheral and Coronary Atherosclerotic Plaque . . . ", J. Clin. Invest., ISSN 0021-9738, Apr. 1993, 1 page.
|Press Release dated Oct. 21, 1996, "Doctor's Demonstrate Proof of Blood Flow Through Open TMR Channels Created with PLC Systems . . . ", 1 page.
|Press/News Release dated Oct. 10, 1996, "Texas Fieart Institute Presents Study Comparing the Use of CO2 . . . ", 1 page.
|Schumacher et al., "Induction of Neoangiogenesis in Ischemic Myocardium by Human Growth Factors", Clinical Investigation and Reports, Dec. 1, 1997, 6 pages.
|Vineberg et al., "Creation of Intramyocardial Pathways to Channel Oxygenated Blood Between Ventricular Arteriolar Zones", Canad. Med. Ass. J., vol. 96, Feb. 4, 1967, 3 pages.
|Vineberg et al., "The Ivalon Sponge Procedure for Myocardial Revascularization", Surgery, vol. 47, No. 2, Feb. 1960, pp. 268-289.
|Vineberg et al., "Treatment of Acute Myocardial Infarction by Endocardial Resection", Surgery, vol. 57, No. 6, Jun. 1965, pp. 832-835.
|Vineberg, A., "Results of 14 Years' Experience in the Surgical Treatment of Human Coronary Artery Insufficiency", Canad. Med. Ass. J., vol. 92, Feb. 13, 1965, 8 pages.
|Walter et al., "Treatment of Acute Myocardial Infarction by Transmural Blood Suply from the Ventricular Cavity", European Surgical Research, 3:130-138 (1971).
|Winslow, R., "Genetic Techniques Succeed in Treating Patients with Obstructed Blood Vessels", The Wall Street Journal, published on or before Nov. 2, 1998, 2 pages.
|Written Opinion, from PCT/US2001/042994, mailed Mar. 24, 2009.
|Citing Patent
|Filing date
|Publication date
|Oct 3, 2013
|Mar 17, 2015
|Preceptis Medical, Inc.
|Stabilization system and aspiration device with rapid diagnostics
|U.S. Classification
|International Classification
|Cooperative Classification
|European Classification
|Jul 6, 2010
Owner name: SCIMED LIFE SYSTEMS, INC., MINNESOTA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ELLIS, LOUIS;HENDRICKSON, GARY L.;HARRISON, KENT D.;AND OTHERS;SIGNING DATES FROM 20020621 TO 20020708;REEL/FRAME:024636/0206
Owner name: SCIMED LIFE SYSTEMS, INC., MINNESOTA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PALASIS, MARIA;BARRY, JAMES J.;REEL/FRAME:024636/0236
Effective date: 20010326
Owner name: BOSTON SCIENTIFIC SCIMED, INC., MINNESOTA
Free format text: CHANGE OF NAME;ASSIGNOR:SCIMED LIFE SYSTEMS, INC.;REEL/FRAME:024636/0266
Effective date: 20041222
|May 21, 2014
|Fee payment
Year of fee payment: 4


text:
Negus, Nathan, 1801-1825
From Library of Congress Name Authority File
Negus, Nathan, 1801-1825
Instance Of
Scheme Membership(s)
Collection Membership(s)
Additional Information
Exact Matching Concepts from Other Schemes
- found: NUCMC data from Pocumtuck Valley Memorial Association Library (Deerfield, Mass.) for Negus family. Papers, 1808-1823 (Nathan Negus; 1801-1825; s. of Joel N., of Deerfield, Mass.)
- found: NY Hist. Soc. Dict. artists in Amer., 1951 (Nathan Negus; 1801-1825; itinerant portrait painter; brother of Joseph and Caroline; b. Petersham, Mass.; studied in Boston; worked in towns in New England and the South)
Change Notes
- 1991-09-19: new
Alternate Formats


text:
Morning briefing
DETROIT — Good morning from Joe Louis Arena, where the Bruins will face off against the Red Wings tonight. The game will air on Versus.
* Zdeno Chara will most likely be matched against Detroit's power line of Tomas Holmstrom, Pavel Datsyuk, and Todd Bertuzzi. Datsyuk has scored two goals and four assists in his last three games. Holmstrom has never scored a goal against the Bruins in 14 career games. Boston is the only team Holmstrom has never scored against.
* The Boston power play (12.2 percent, 29th in the league) will go up against the Detroit penalty kill (72.7 percent, 28th in the NHL).
* The Wings average 9.3 penalty minutes per game, fewest in the NHL.
* Dan O'Halloran and Kevin Pollock will be the referees. Shane Heyer and Greg Devorski will be the linesmen.


text:
A #zazzle update: New #print https://www.zazzle.com/creatively_modern_abstract_fractal_print-256646576910693137?social=true&view=113984608219979320 and an old #sticker recently sold https://www.zazzle.com/a_white_house_autumn_trees_classic_round_sticker-217803913928180730 #art #prints #patterns #futurist #linandaras_art #autumn #fall #design #abstract #creativity #orange #creatively
… still playing with Bluegreen, and Gold, Acrylic, and Ink, … My Artwork, My Art, Drawing, Illuminated, Close-up, Black Background, Indoors , Day, No People, Art, ArtWork, Arte, Paintings, Pens, Creativity, Creative, Miniatures, Canvas, Detail, Uk, Green Color by Alexandra Cook on EyeEm
… trying to put more thought and effort in my Work, … Painting, Art, ArtWork, Acrylic Painting, Painting In Progress, Nature, Outdoors, Multi Colored, Trees, Blue Flowers, Branches, Spring, Green, My Art, Creativity, Work In Progress, Business, Day, No People, Backgrounds, Canvas, рисунок, Arte, Pintura by Alexandra Cook on EyeEm
… Drawing, with Acrylics, & Ink, on top of fixed Soft Pastels, … Close-up, Leaf, Green Color, Full Frame, Art, ArtWork, Creativity, Creating, Experimenting…, Painting, My Art, Artists At Work, Fingers, Artists At Play, Sunlit, Plants, Kalanchoe, Stylized, Canvas, Pen, рисунок by Alexandra Cook on EyeEm
… Bluebells, starting to appear. .. Work In Progress, Painting, Acrylic, Canvas, Art, ArtWork, Acrylic Painting, Spring, Work, Working, Miniature, Brush Strokes On Canvas, Blue, Green, Creativity, No People, Multi Colored, Day, Outdoors, Hazelwood, Wales, рисунок, рисую at Newtown by Alexandra Cook on EyeEm
… the Beginning, of Something New, … Art, Creativity, No People, Multi Colored, Painting, Drawing, ArtWork, Sketch, Sketching, Trees, Flowers, Beginnings, My Art, My Artwork, Arte, рисунок, набросок, Colorful, Create, Be Creative, Improvisation, Working, Творчество by Alexandra Cook on EyeEm
… well, when I started this Painting, yesterday I thought it will be a nice cute Valentine Card, Design, . Of course, it went quite far in a Surrealistic, direction since … Drawing – Art Product, Close-up, Artists Life, Art, ArtWork, Hearts, Heart, Tree, Cloud, Stars, Paintbrush, Acrylic Painting, My Artwork, Creativity, рисунок, Arte, Brush, Love, Bleeding Heart , Roots, Surrealism by Alexandra Cook on EyeEm
… Working, on an old Kalanchoe, Painting, … Human Hand, Creativity, Art And Craft, One Person, Holding, Real People, Lifestyles, Drawing – Art Product, Artist, Pattern, People, Close-up, Indoors , Human Body Part, Multi Colored, Adult, Adults Only, Paintbrush, Flowers, Acrylicpainting , Pink by Alexandra Cook on EyeEm
… Red, … (photography+ Drawing, + Digital Collage, ) Pattern, Art And Craft, Creativity, Flowers, Black, Green, Pelargonium, Collage, My Art, My Artwork, Bright, Festive, Colorful, коллаж, герань, узор, цветы, Folk Art by Alexandra Cook on EyeEm
… this little Painting, is at an exhibition of the Shrewsbury Visual Arts Network in the former "42nd Street's" gallery. Inspired by Landscapes, of Portugal as seen from a train window. Art And Craft, Painted Image, Creativity, Drawing – Art Product, Artist's Canvas, Fine Art Painting, Acrylic Painting, Painter – Artist, Artist, Pine Trees, Pinea, Trees, Pinus Pinea, Mediterranean , My Art, My Artwork, Arte, рисунок, сосны by Alexandra Cook on EyeEm
Playa de los locos Sketch, … Painted Image, Drawing – Art Product, People, Drawing – Activity, Water, Creativity, Beach, Sand, Sketching, Playa, Torrevieja, Acrylic, Art, Painting, My Artwork by Alexandra Cook on EyeEm
… "she doesn't sit and wait" … Sketch, Face, Collage, Art, ArtWork, Strong Woman, Creativity, Exploration, Green Color, My Art, My Artwork, рисунок, набросок, голова , портрет, Mixed Media, Arte by Alexandra Cook on EyeEm


text:
- select colour
it's an internet thing!
it's an internet thing!
12:08 20 January 2014
On Friday, gaming giant Nintendo issued a profits warning saying that it will make an operating loss of £205m. Following the announcement, its share nosedived by as much as 18per cent on Monday.
Initially, it forecasted an operating profit of 100bn yen for the period but this has since been revised.
The lower-than-expected profit is blamed on weak Wii U console sales during the holiday season. Based on forecast, the company only sold 2.8 million units, which is 70per cent less than the initial forecasted sales of nine million. In addition, it also reduced the sales forecast for its 3DS console from 18 million to 13.5 million units.
Nintendo, which is the maker of world famous titles Super Mario and Donkey Kong, experienced global success when it first released its original Wii game console.
During this time, the company's share reached record high in 2007. However, in July last year, UK supermarket chain Asda said it would no longer sell Wii U in its store. The stiff competition from rival console makers, which include Xbox One and PlayStation 4 added to the downfall.
Disclaimer: Supanet is not responsible for, and disclaims any and all liability for the content of comments written by contributors to this website


text:
Netflix's new Fast engine tracks your Netflix speed
Sick of watching spinning wheels while you'd rather be watching Netflix? There's a new tool that could show you why.
Internet speed tracking engines are nothing new at all, but when Netflix talks about Internet speeds, people listen. The company already offered up speed data on a global level, including Australia, via its Netflix ISP Speed Index, where for April 2016 it ranks Optus, TPG, iiNet, Exetel, Dodo/Primus and Telstra respectively as the six fastest ISPs on average.
Averages only tell you what the crowd is doing, however, and don't do that much to relate to what your own individual connection is capable of. This is important in the case of Netflix, because it uses adaptive streaming to deliver you the best possible picture quality depending on the material you're watching. In theory, if you've got fast enough Internet pipes, you can watch Daredevil in 4K resolution, but how do you know?
Netflix's new "Fast" speed engine is designed to give you those kind of individual numbers, delivering a straight download speed estimate at the time of testing based on connections to Netflix's global servers. It's a deliberately stripped-down tool designed only to give you a straight download speed, because other factors such as uploads or ping rates aren't relevant for Netflix watching.
You can check your Netflix speed ranking at Netflix's new fast.com web site here.


text:
A rural Ontario farm is again the epicentre of a Toronto police search, with forensic officers and a drug unit focused this time on a dilapidated barn in their search for clues in the disappearance of a friend of murder suspect Dellen Millard.
Officers are investigating the disappearance of Laura Babcock, who went missing in July, 2012, as well as the death of Mr. Millard's father, Wayne. Dellen Millard is also accused in the murder of Ancaster, Ont., father Tim Bosma.
Detective Mike Carbone confirmed this latest search is related to the young woman, though he wouldn't say what led officers back to the property south of Kitchener, Ont. A police spokesperson would say only that the warrant was prompted by "further information."
The search began around 8 a.m. on Monday and extended until the early evening, deepening in intrigue as members of the Waterloo Regional Police drug unit put on white jumpsuits, blue gloves and black ventilator masks to briefly enter the barn's two roadside entrances.
Police didn't leave with any physical evidence Monday and planned to continue their search – likely Tuesday – a Toronto officer said as the effort wound down around 6 p.m.
The barn, with its rusting roof and cracked wooden frame, has attracted national attention ever since Mr. Bosma's charred remains were found on the 100-acre property in May. Hamilton Police are investigating the death of Mr. Bosma, who went missing after taking two men to test drive his pickup truck on May 6.
In the spring, officers seized a portable livestock incinerator, which was purchased by an employee of Mr. Millard's aviation company around July, 2012. Mr. Millard, 28, and Mark Smich, 26, face charges of first-degree murder in relation to Mr. Bosma's death.
Toronto officers searched Mr. Millard's property later in May, using a backhoe and a hand-held metal detector, but at the time said "no evidence was located." That search was in relation to both Ms. Babcock – a friend of Mr. Millard who phoned him several times before she disappeared – and his father, whose Nov. 29, 2012, death was initially deemed a suicide.
On Monday, officers devoted their attention to the barn, taking notes and pictures as they went back and forth between the structure and a white Toronto Police Forensic Identification Services truck parked at the scene.
Earlier in the day, Ms. Babcock's aunt, Lori Ryan, said she feared police were on site in connection to her niece, calling the timing of the incinerator delivery and Ms. Babcock's disappearance "too fishy."
"I believe they're looking for Laura – and I'm sorry [if] they're looking for Laura," Ms. Ryan said.
Ms. Babcock and Mr. Millard had begun a sexual relationship in the first half of 2012 while Mr. Millard had a girlfriend, said Shawn Lerner, Ms. Babcock's ex-boyfriend and close friend. Mr. Millard later told Mr. Lerner that Ms. Babcock had been asking him for drugs and a place to stay, which Mr. Millard said he declined.
Mr. Millard's lawyer, Deepak Paradkar, said he didn't know why police had returned to his client's farm. "I don't know anything about any new information."


text:
Is there a chance i could have infertility problams
Patient : Hi I was just wondering if you have a wond ultra sound to check for cycts on the ovaries would they check if everything else was normal or just the ovaries and if not would they have told me if I could have any children , my ovaries result was fine tho?
Symptoms: Being trying for a baby for a while
Doctor : Thank you for your query. After carefully going through your query we would like to convey that if the couple have been trying to conceive & have not been able to a conception even after an year then such couples could be termed as infertile. There are around twelve to thirteen reasons which could lead to infertility in both the male & female partners it is advisable that the couple undergo these investigations to ascertain the reason for infertility based on the reports appropriate treatment could be suggested ranging from simple medication to advanced ART( assisted reproductive technologies) to help overcome infertility problems thereby achieving your dream of parenthood. The transvaginal ultrasound scan will help to know the ovulation & cysts also if there are any. Depending on the size of the cysts they could either resolve automatically if small or may require aspiration if they are big as these could hinder ovulation by impairing folliculogenesis(growth of the egg) needs medical attention. Therefore get a repeat scan done to analyse the present situation based on which appropriate advice can be suggested. Hope that answers your query. Have a good day.
Related Q&A
In February I had a hysteroscopy on day 14 of
Q: In February I had a hysteroscopy on day 14 of my cycle where the gynaecologist discovered a large polyp hanging from ...
My wife and I are both 44 years old We
Q: My wife and I are both 44 years old. We previously did not want to have babies. However we are now thinking to have b...
Is 300 total testosterone normal for a 30 year old male?
Q: Is 300 total testosterone normal for a 30 year old male?
As long as when I produce semen when I masturbate
Q: As long as when I produce semen when I masturbate that means I can have kids. Correct?
Would like to get a professional's advice on my blood
Q: Would like to get a professional's advice on my blood work results. I'm mainly looking to find out if anything on her...
Dr. James Obaji M.D.
- 247 Reviews
- Family Physician
Dr. Suneel Sharman M.D.
- 190 Reviews
- Family Physician
Dr. Pat Golden M.D.
- 169 Reviews
- Cardiologist
Dr. Kunaal Jindal M.D.
- 112 Reviews
- Plastic Surgeon


text:
Osage teen vows to dye hair for MS
Danika Larsen said a few years ago when her favorite uncle, Adam Pratt, was diagnosed with multiple sclerosis, it crushed her because heroes aren't supposed to get sick.
In May, 18-year-old Danika is participating in Walk MS in honor of her uncle. It will be held in the Park Rapids Elementary School,
"I didn't know we had MS in our family before," she said. "He has always been my hero. He was the strongest guy I knew ... It kind of shocked me to know he had that disease."
She read up on MS, but it didn't hit her until last year when he started showing the symptoms of the disease.
"He got hurt a lot more, and he's my hero and he's not supposed to get hurt. When he did get hurt, it was really upsetting."
Her mom walked in Walk MS previously, and is returning this year as part of Larsen's team -- Team Pratt. Her friend, Georgia Booker, will also be on the team of walkers.
"I wanted to do it this year, and I thought he'd like it. And he does," Larsen said of her uncle's support for the team. "He thinks it's fantastic."
Larsen's goal is to raise $400 for Walk MS, and she has some incentive for her donors. If she can raise the money by her birthday, April 25, she will dye her hair orange -- and keep it that way.
"My hair color will be permanent because the disease is permanent," she said.
She also plans to go to Fargo a couple times and "dress kind of crazy" to spread the word about MS, "and maybe people will give us donations."
Those interested in donating to Larsen and her cause can either send checks to her home address at 21525 470th Ave., Osage, MN 56570 or donate online at walkmnm.nationalmssociety.org and search for Team Pratt.